Search filters
Filters
Clear All

Phase

  • 4
  • 14
  • 8
  • 1
  • 5
  • 3
  • 38
  • 21
  • 38
  • 36
  • 2
  • 38

Found 38 Leukemia trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Study of Investigational Medication for Refractory/Relapsed AML

18 years - 80 years
All genders
Phase 2/3
Interventional
This study investigates the use of an investigational medication in combination with another medication for treating adults who have acute myeloid leukemia (AML) that has not responded to previous treatment or has returned after treatment. The purpose of the study is to find out if this combination can help in …
Learn More

UPCC 08422 A Phase 1b/2 Open-Label Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody -CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richters Syndrome

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
Program with 2 clinical trials

Test1234-Penn

Penn Test 123
Check Eligibility
Program with 2 clinical trials

P1

Formal Test Program
Check Eligibility
Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

99 years or below
All genders
Phase 1
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
Learn More

UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
Learn More
Program with 5 clinical trials

V7.2 smoke testing program

Test
Check Eligibility
UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

UPCC 38417: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

99 years or below
All genders
TBD
Learn More
31 - 38 of 38